Skip to main content


O12 - Specific IgE levels for goat’s and sheep’s milk after successful oral immunotherapy to cow’s milk in children

Article metrics

  • 567 Accesses


Cow’s milk (CM) oral immunotherapy has proven to be effective as a treatment for persistent CM allergy. Allergic reactions to goat and sheep cheeses have been described in almost 25% of patients desensitised to CM, indicates that immunotherapy is specific for each milk.


To describe changes of goat’s IgE and sheep’s IgE in patients who tolerated CM after a CM oral immunotherapy.


24 children aged between 4 and 13 who achieved tolerance to milk after CM immunotherapy were included. Specific IgE to cow’s caseine, sIgE to whole goat’s milk and sIgE to whole sheep’s milk at baseline and at 24 months follow up were analised (CAP-Phadia). The patientes were classified in two groups: high risk (17 patients) and low risk (7 patients) based on the premedication need, number of adverse reactions and time to achieve a complete tolerance to CM.


The median of Specific IgE to CM casein, goat’s whole milk, sheep’s whole milk a baseline were 24.3KU/L, 31.2KU/L and 27.4KU/L and 9.5KU/L, 16.9KU/L and 17.3KU/L after 24 months of follow up (p<o,o5).In the high risk patients the median of Specific IgE to CM casein, goat’s whole milk, sheep’s whole milk were 33.7KU/L, 43.7KU/L and 37.1KU/L at baseline and 13.1KU/L, 23.9KU/L and 23.6KU/L after 24 of follow up (p<o,o5). In contrast, in the low risk group the specific IgE to CM casein, goat’s whole milk, sheep’s whole milk did not shown a significant decrease after 24 of follow up. 4 patients showed a different patron referred to IgE-goat’s milk and IgE-sheep’s milk compared with CM, independently of risk group.


We found a decrease of IgE levels to whole goat´s and sheep´s milk after oral immunotherapy to CM.

Author information

Correspondence to Liseth Villafana.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article


  • Public Health
  • High Risk
  • Adverse Reaction
  • High Risk Patient
  • Risk Group